Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.
Payne described Arcturus as a “next generation messenger RNA medicines company” based in San Diego with about 100 employees. He said the company used its technology during the pandemic to support vaccination efforts in Singapore, Vietnam and Japan, and that its COVID-19 vaccine, Kostaive, is now approved in 32 countries, including Japan, the United Kingdom and the European Union.